Abbott Gets FDA Approval for AI-Powered Imaging Tech
Abbott Gets FDA Approval for AI-Powered Imaging Tech
DJ Abbott Gets FDA Approval for AI-Powered Imaging Tech
DJ雅培公司获得FDA批准使用人工智能成像技术
By Matt Grossman
马特·格罗斯曼(Matt Grossman)著
Abbott Laboratories has gotten an approval from the U.S. Food and Drug Administration for imaging software that uses artificial intelligence to visualize coronary blood flow and blockages.
雅培实验室已经获得美国食品和药物管理局(U.S.Food and Drug Administration)的批准，可以使用人工智能可视化冠状动脉血流和阻塞的成像软件。
The Abbott Park, Ill.-based medical-device maker had already received European approval for the technology, an optical coherence tomography imaging platform using Abbott's Ultreon software.
这家总部位于伊利诺伊州雅培公园(Abbott Park)的医疗设备制造商已经获得了欧洲对该技术的批准，这是一种使用雅培Ultreon软件的光学相干层析成像平台。
The technology can help doctors improve treatment plans, Abbott said. "As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care," said Dr. Nick West, Abbott's chief medical officer for its vascular business.
雅培说，这项技术可以帮助医生改进治疗计划。雅培公司负责血管业务的首席医疗官尼克·韦斯特(Nick West)博士说：“随着心脏科医生继续采用OCT，远离血管造影术等传统成像方法，新兴技术在确定最佳患者护理方案方面起到了关键作用。”
Write to Matt Grossman at matt.grossman@wsj.com
写信给马特·格罗斯曼(Matt Grossman)，电子邮件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
August 03, 2021 09:12 ET (13:12 GMT)
2021年08月03日09：12美国东部时间(格林尼治标准时间13：12)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司